Beta-Hydroxybutyrate Enhances BDNF Expression by Increasing H3K4me3 and Decreasing H2AK119ub in Hippocampal Neurons.
Level 5 - mechanism / opinion, no new human data
in vitro bench/cellular research in hippocampal neurons
PubMed 33192276 · doi:10.3389/fnins.2020.591177
What was done
The study investigated the molecular and epigenetic mechanisms by which beta-hydroxybutyrate (BHBA) regulates brain-derived neurotrophic factor (BDNF) expression in hippocampal neurons. The authors measured changes in histone modifications (H3K4me3 and H2AK119ub) at Bdnf promoters I, II, IV, and VI as well as globally, and evaluated the involvement of L-type calcium channels and the Ca2+/CaMKII/CREB signaling cascade.
What was found
No quantitative values, effect sizes, or statistical metrics were reported in the abstract. BHBA treatment increased H3K4me3 occupancy and decreased H2AK119ub occupancy at Bdnf promoters I, II, IV, and VI and at the global level in hippocampal neurons. These histone changes were dependent on L-type calcium channels. BHBA-activated L-type calcium channels triggered Ca2+/CaMKII/CREB signaling, promoting the binding of p-CREB and CBP to Bdnf promoters to drive BDNF expression.
Why it matters
This work outlines a direct epigenetic mechanism linking ketone body exposure to neurotrophin regulation in neurons, providing cellular context for how beta-hydroxybutyrate may support central nervous system function.
Limits
This is purely an in vitro cell culture study with no human or in vivo animal validation. The abstract reports no sample sizes, BHBA concentrations, exposure durations, effect magnitudes, or confidence intervals.
Cited by
- supports Ketone bodies, such as beta-hydroxybutyrate, activate brain-derived neurotrophic factor (BDNF) in the brain.